tldrdailynews.com logo
Tag

Mrna Therapy

All articles tagged with #mrna therapy

NIH Launches Public-Private Cancer Vaccine Initiative to Accelerate Personalized Treatments
health-and-biotech3 days ago

NIH Launches Public-Private Cancer Vaccine Initiative to Accelerate Personalized Treatments

The National Institutes of Health (NIH) is launching a public-private partnership in December to accelerate the development of personalized cancer vaccines. This initiative, modeled after the rapid success of COVID-19 vaccines, aims to reduce the timeline for bringing new treatments to market from 8-15 years to 7-10 years. The program will initially focus on pancreatic, liver, and colorectal cancers, as well as pediatric tumors. The announcement triggered a significant rally in vaccine-related stocks, with Novavax and Moderna leading gains, driven by the promise of faster clinical trials and reduced R&D costs for participating companies.

via Yahoo Finance|
#biotech-stocks#cancer-vaccines#clinical-trials
Novartis Secures Chinese mRNA Therapy in $7.8B Deal Amid Pipeline Pressures
biopharmaceuticals11 days ago

Novartis Secures Chinese mRNA Therapy in $7.8B Deal Amid Pipeline Pressures

Novartis has agreed to pay up to $7.8 billion for exclusive worldwide rights to ABO2203, an early-stage mRNA-based T-cell engager developed by Chinese biotech Abogen Biosciences. The agreement includes a $575 million upfront payment and up to $7.2 billion in milestone payments. The therapy targets autoimmune diseases by depleting B cells using an in vivo approach that avoids traditional manufacturing complexities. This deal follows recent setbacks in Novartis’s own CAR-T programs and reflects a broader trend of Western pharmaceutical companies partnering with Chinese developers to secure future pipeline growth.

via Endpoints News|
#abogen-biosciences#autoimmune-disease#biopharmaceuticals
Novartis Acquires Chinese Autoimmune Therapy for $7.8B Amid Patent Cliff Pressures
biotechnology11 days ago

Novartis Acquires Chinese Autoimmune Therapy for $7.8B Amid Patent Cliff Pressures

Novartis has agreed to pay up to $7.8 billion for Abogen Biosciences' mRNA-based T-cell engager, ABO2203, targeting autoimmune diseases. The deal includes a $575 million upfront payment and grants Novartis global rights to the asset plus an option to license other RNA-platform assets. This move follows recent setbacks in Novartis's CAR-T programs and reflects a broader trend of Western pharma companies partnering with Chinese biotechs to secure future pipeline growth.

via Fierce Biotech|
#abogen-biosciences#autoimmune-disease#biotechnology
health17 days ago

mRNA Cocktail Erases Pancreatic Tumors in Half of Mice

A new mRNA-based immunotherapy has shown unprecedented success in animal models of pancreatic cancer. Researchers at UMass Chan Medical School developed a single injection combining five cytokine mRNAs and three tumor-associated antigens. In mice with pancreatic ductal adenocarcinoma, approximately 50% experienced complete tumor regression that lasted up to one year after treatment stopped. The therapy works by weakening the fibrotic barrier around tumors and training the immune system to recognize cancer cells, potentially creating long-term immune memory. While mouse results do not guarantee human success, the team is developing an IND-ready product for clinical trials.

via SciTechDaily|
#health#immunotherapy#mrna-therapy
Cancer Vaccine Market Set to Hit 36% CAGR as mRNA Breakthroughs Expand Beyond Melanoma
health-and-biotech21 days ago

Cancer Vaccine Market Set to Hit 36% CAGR as mRNA Breakthroughs Expand Beyond Melanoma

The global cancer vaccine market, valued at $335 million in 2025, is projected to grow at a 36% compound annual rate through 2036. This expansion is driven by the recent Phase 3 success of Moderna and Merck’s personalized mRNA vaccine for melanoma, alongside a broadening pipeline targeting lung, prostate, and pancreatic cancers. While the US dominates current sales, analysts note a persistent gap between early immune responses and late-stage clinical efficacy.

via PR Newswire|
#cancer-vaccines#health-and-biotech#immunotherapy
Personalized cancer vaccine from Moderna and Merck shows breakthrough in melanoma
health1 month ago

Personalized cancer vaccine from Moderna and Merck shows breakthrough in melanoma

Moderna and Merck reported a personalized mRNA cancer vaccine used with Keytruda that reduced melanoma recurrence and spread in a trial of more than 1,000 patients, with five-year data from earlier results showing about a 50% drop in recurrence and a 59% drop in spread versus Keytruda alone; if approved, thousands of melanoma patients could benefit in the first years, and trials in other cancers (lung, bladder, kidney, pancreatic, stomach) are ongoing with results expected in the coming years.

via CNN|
#cancer-vaccine#health#keytruda
Sugar-Coated Nanoparticles Deliver mRNA to Brain Tumors in Mice
science2 months ago

Sugar-Coated Nanoparticles Deliver mRNA to Brain Tumors in Mice

Researchers at Oregon State University used mannose-cholesterol coated lipid nanoparticles to cross the blood–brain barrier and deliver tumor-suppressing PTEN mRNA to glioblastoma in mice, greatly reducing tumor burden and extending survival without detectable organ toxicity. While promising, the results are preclinical and in animals, but the approach could become a general platform for brain-targeted mRNA therapies and other neurological applications.

via ScienceAlert|
#blood-brain-barrier#drug-delivery#glioblastoma
OSU’s Nanoparticles Target Lung Tumors and Muscle Wasting
science6 months ago

OSU’s Nanoparticles Target Lung Tumors and Muscle Wasting

Oregon State University researchers report lipid nanoparticles that bind vitronectin in the bloodstream to home in on lung tumors and deliver follistatin mRNA, reducing tumor burden about 2.5-fold more than conventional LNPs in mice, while also countering cancer cachexia by preserving appetite, weight, and muscle—preclinical results with human testing to come.

via SciTechDaily|
#cachexia#lipid-nanoparticles#lung-cancer
Capsule-Filtration-Enabled LNPs Target Pancreas for Precision mRNA Therapies
science7 months ago

Capsule-Filtration-Enabled LNPs Target Pancreas for Precision mRNA Therapies

A Nature study introduces AH-LNP, a pancreatic-targeted lipid nanoparticle whose protein adsorption enlarges it to enable capsule-filtration–driven pancreas accumulation and receptor-mediated uptake, allowing efficient delivery of Cas9 mRNA and sgRNA for genome editing as well as mRNA encoding therapeutic cytokines. The approach yields precise pancreatic gene editing, enhances antitumor responses when combined with vaccines or CAR-T therapy across multiple pancreatic cancer models, and shows safety in several animal models including non-human primates, highlighting a promising platform for precision treatments of pancreatic diseases.

via Nature|
#ah-lnp#crispr-cas9#lipid-nanoparticles
Liver signals rekindle aging immune response in mice
health8 months ago

Liver signals rekindle aging immune response in mice

Broad Institute researchers show in old mice that injecting mRNA into the liver triggers thymic signals (DLL1, FLT3-L, IL-7), reviving T-cell production. Over four weeks, older mice had more diverse T cells, stronger vaccine responses, and better anti-cancer activity, though the boost was temporary and human trials are needed, with the findings published in Nature.

via ScienceAlert|
#aging#health#immunology
mRNA Therapy Revitalizes Aging Immune System and Enhances Disease Response
health-and-medicine10 months ago

mRNA Therapy Revitalizes Aging Immune System and Enhances Disease Response

The study presents a novel approach to counteract immune decline in aging by using mRNA delivered to the liver to produce key immune factors (DLL1, FLT3-L, IL-7), which rejuvenates T cell production, enhances vaccine responses, and improves tumor immunotherapy efficacy in aged mice, without adverse effects or autoimmunity.

via Nature|
#health-and-medicine#immune-aging#immunotherapy